[Hypoxia: a therapeutic target].
Fernández-Braña
Miguel
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015687:Cell Hypoxia / Q000187:drug effects*; D003497:Cyclic N-Oxides / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006019:Glycolysis; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000502:physiology; D009363:Neoplasm Proteins / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D010084:Oxidation-Reduction; D010100:Oxygen / Q000378:metabolism; D011809:Quinones / Q000494:pharmacology / Q000627:therapeutic use; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019163:Reducing Agents / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D003497:Cyclic N-Oxides; D051793:Hypoxia-Inducible Factor 1; D009363:Neoplasm Proteins; D009593:Nitroimidazoles; D011809:Quinones; D011838:Radiation-Sensitizing Agents; D019163:Reducing Agents; D010100:Oxygen